VI
Vimta Labs Ltd (VIMTALABS)
₹467.65
Mkt cap
₹2,230 Cr
P/E ratio
27.40
P/B
4.25
Div yield
0.40%
ROE
18.90%
ROCE
25.20%
EPS (TTM)
₹17.07
Book value
₹110
52W range
376–675
Sector
Healthcare
Price history
Previous close
Incorporated in 1990, Vimta Labs Ltd is a contract research and testing services provider [1]
NSE VIMTALABSBSE 524394
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−30.72% from high₹468
₹376+24.36% from low₹675
Current
₹467.65
Prev close
₹471.95
Day
−0.91%
Price performance
1D
−1.05%
1W
−6.39%
1M
−4.59%
3M
−27.08%
6M
+3.71%
1Y
−26.88%
YTD
−23.36%
Financials
Revenue, profit & margin
P/E ratio
27.4×
VIMTALABS is 4% above the sector median of 26.4×
VIMTALABS27.4×
Sector median26.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 64 | 73 | 73 | 75 | 85 | 90 | 94 | 98 | 102 | 99 | 109 | 109 | 112 | |
| YoY Sales growth | -19% | -5% | -10% | -9% | +32% | +23% | +30% | +30% | +20% | +10% | +16% | +12% | +10% | |
| Expenses | 48 | 50 | 47 | 49 | 55 | 57 | 61 | 64 | 68 | 64 | 70 | 72 | 74 | |
| Operating Profit | 17 | 23 | 26 | 26 | 30 | 33 | 33 | 34 | 34 | 34 | 39 | 37 | 38 | |
| OPM % | 26% | 31% | 36% | 35% | 35% | 37% | 35% | 35% | 34% | 35% | 36% | 34% | 34% | |
| Other Income | 0 | -1 | -1 | -1 | -1 | 5 | 2 | 2 | 3 | 0 | 3 | 4 | 3 | |
| Interest | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 9 | 8 | 8 | 8 | 8 | 10 | 9 | 10 | 10 | 11 | 13 | 13 | 13 | |
| Profit before tax | 8 | 13 | 16 | 17 | 20 | 28 | 25 | 25 | 26 | 23 | 29 | 28 | 28 | |
| Tax % | 25% | 25% | 24% | 26% | 24% | 23% | 27% | 25% | 24% | 25% | 27% | 26% | 25% | |
| Net Profit | 6 | 9 | 12 | 12 | 15 | 22 | 18 | 19 | 20 | 18 | 21 | 21 | 21 | |
| EPS in Rs | 1.34 | 2.14 | 2.79 | 2.77 | 3.44 | 4.84 | 4.12 | 4.24 | 4.47 | 3.94 | 4.73 | 4.71 | 4.61 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.27% · closed higher next day 1 of last 1
| Q2FY27 | |
|---|---|
| Broadcast | 30 Oct '26 |
| Earnings day | −0.27% |
| +1 day | +0.13% |
| +5 days | +4.04% |
| +15 days | — |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202635.64%Promoter
Promoters35.64%0.02
FIIs5.07%0.66
DIIs0.48%0.11
Public58.79%0.76
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Syngene Intl. | ₹444.30 | 67.46 | 17,935 | 0.28% | 32 | −45.17% | 833 | −8.55% | 9.99% |
| Indegene | ₹666.20 | 37.64 | 16,055 | 0.34% | 112 | +9.99% | 1,122 | +39.55% | 18.82% |
| Suven Life Scie. | ₹277.80 | — | 7,850 | 0.00% | −107 | −38.33% | 1 | +30.43% | −79.54% |
| Vimta Labs | ₹498.90 | 27.37 | 2,230 | 0.40% | 21 | +3.46% | 112 | +9.95% | 25.23% |
| Fabtech Tech. | ₹139.78 | 20.87 | 621 | 0.43% | 15 | −67.06% | 92 | −24.19% | 13.88% |
| Novelix Pharma. | ₹70.05 | 42.89 | 199 | 0.00% | 2 | +194.34% | 45 | +23.02% | 10.87% |
| Bilcare | ₹84.43 | 5.46 | 199 | 0.00% | 1 | +175.74% | 248 | +39.41% | 7.06% |
| Median: 9 Co. | ₹139.78 | 26.38 | 621 | 0.00% | 3 | +9.99% | 92 | +26.73% | 10.87% |
Filings
Annual reports15
Concall transcripts50
TranscriptNov 2026PPTNov 2026RECNov 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025RECJul 2025PPTJul 2025PPTJul 2025TranscriptMay 2025PPTMay 2025RECMay 2025PPTApr 2025
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 4 Nov - Transcript of the FY / Q2 - 2026-27 Earnings / Investor Call held on 30th October 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 31 Oct - Newspaper Publication of Unaudited Financial Results - Q2 FY 2026-27Announcement under Regulation 30 (LODR)-Acquisition 30 Oct - Vimta Labs incorporated wholly owned subsidiary Vimta Labs LLC in USA on 24 Sep 2026; investment USD 8,500.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Oct - Audio recording of Q2 FY2026-27 earnings call uploaded on company website.Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Oct - Vimta Labs reported Q2 FY27 income of ₹1,149 Mn and H1 PAT of ₹417 Mn.


